Latest Pharma Insights
US Consumers’ Tight Budgets Prompted Value Shift In Beauty, Less M&A Activity In 2025
Middle- and low-income US consumers are more thoroughly scrutinizing discretionary purchases, boosting mass market beauty sales in 2025 and prompting beauty companies to reposition their portfolios through reformulation, price reductions and packaging changes, says Capstone Partners.
HBW Insight - December 18, 2025
Middle- and low-income US consumers are more thoroughly scrutinizing discretionary purchases, boosting mass market beauty sales in 2025 and prompting beauty companies to reposition their portfolios through reformulation, price reductions and packaging changes, says Capstone Partners.
HBW Insight - December 18, 2025
Execs On The Move: December 8–12, 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - December 18, 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - December 18, 2025
Finance Watch: Athira Licenses Breast Cancer Drug, Raises Cash To Develop It
Public Company Edition: Athira licensed Phase III lasofoxifene from Sermonix and raised $90m plus up to $146m from warrants. Also, Immunovant, Immunome and Kodiak grossed $550m, $400m and $160m respectively, in follow-on offerings. Vor garnered $150m in a private placement.
Scrip - December 18, 2025
Public Company Edition: Athira licensed Phase III lasofoxifene from Sermonix and raised $90m plus up to $146m from warrants. Also, Immunovant, Immunome and Kodiak grossed $550m, $400m and $160m respectively, in follow-on offerings. Vor garnered $150m in a private placement.
Scrip - December 18, 2025
Lilly Eyes Quick FDA Approval For Orforglipron In Obesity, While Novo Submits CagriSema
Lilly, which has a Commissioner’s National Priority Voucher for the oral GLP-1, revealed orforglipron maintained weight loss in patients switching from Wegovy or Zepbound.
Scrip - December 18, 2025
Lilly, which has a Commissioner’s National Priority Voucher for the oral GLP-1, revealed orforglipron maintained weight loss in patients switching from Wegovy or Zepbound.
Scrip - December 18, 2025
Takeda’s Zasocitinib Marks Another Win In Late-Stage Pipeline Strategy
The drugmaker announced positive topline results from its two Phase III trials of zasocitinib, a TYK2 inhibitor, in plaque psoriasis.
Scrip - December 18, 2025
The drugmaker announced positive topline results from its two Phase III trials of zasocitinib, a TYK2 inhibitor, in plaque psoriasis.
Scrip - December 18, 2025
FDA Announces ‘Common-Sense’ Reform, Expands RWE Use In Medical Device Reviews
The US FDA has made incorporating real-world evidence into medical device decisions a lot easier. The agency now says it will accept RWE without requiring it to contain identifiable individual patient data, making more of it available. Many stakeholders welcomed the change.
Medtech Insight - December 18, 2025
The US FDA has made incorporating real-world evidence into medical device decisions a lot easier. The agency now says it will accept RWE without requiring it to contain identifiable individual patient data, making more of it available. Many stakeholders welcomed the change.
Medtech Insight - December 18, 2025
Opella Study Finds ‘Significant Variation’ In Probiotic Quality In India
Only Opella’s own Enterogermina brand was found by a company-funded study to be contamination-free, to contain the claimed content, and show resistance to all tested antibiotics.
HBW Insight - December 18, 2025
Only Opella’s own Enterogermina brand was found by a company-funded study to be contamination-free, to contain the claimed content, and show resistance to all tested antibiotics.
HBW Insight - December 18, 2025
Vision Healthcare Grows VMS Offering With Sweden’s BioSalma
Vision Healthcare adds an established supplements portfolio, alongside a robust omni-channel set-up across the Nordics, with the acquisition of BioSalma.
HBW Insight - December 18, 2025
Vision Healthcare adds an established supplements portfolio, alongside a robust omni-channel set-up across the Nordics, with the acquisition of BioSalma.
HBW Insight - December 18, 2025
Padcev/Keytruda Combo Chalks Up Another Bladder Cancer Win
Positive topline data from the EV-304/KEYNOTE-B15 Phase III trial in cisplatin-eligible muscle invasive bladder cancer follows hot on the heels of the combination's stellar results in chemotherapy-ineligible patients.
Scrip - December 18, 2025
Positive topline data from the EV-304/KEYNOTE-B15 Phase III trial in cisplatin-eligible muscle invasive bladder cancer follows hot on the heels of the combination's stellar results in chemotherapy-ineligible patients.
Scrip - December 18, 2025
Biotech Leader Afeyan Warns That ‘Scientific Method Is Under Attack’ In The US
The Flagship Pioneering founder warned the assault on science would not stop at mRNA technology or vaccines and urged the biopharma sector to speak up.
Scrip - December 18, 2025
The Flagship Pioneering founder warned the assault on science would not stop at mRNA technology or vaccines and urged the biopharma sector to speak up.
Scrip - December 18, 2025
Insmed’s Brensocatib Hits The Buffers In Sinusitis
Insmed’s brensocatib has comprehensively failed in a mid-stage study in chronic rhinosinusitis, which would have been a second potential blockbuster indication for the DPP1 inhibitor.
Scrip - December 18, 2025
Insmed’s brensocatib has comprehensively failed in a mid-stage study in chronic rhinosinusitis, which would have been a second potential blockbuster indication for the DPP1 inhibitor.
Scrip - December 18, 2025
Chime Biologics Partners With Libang Pharmaceuticals On A Biosimilar To Amgen’s Blincyto
Glancing over at the changing development requirements for biosimilars in the US and Europe, the Chinese duo Chime Biologics and Beijing Libang Pharmaceutical are allying to develop a blinatumomab biosimilar rival to Amgen’s Blincyto.
Generics Bulletin - December 18, 2025
Glancing over at the changing development requirements for biosimilars in the US and Europe, the Chinese duo Chime Biologics and Beijing Libang Pharmaceutical are allying to develop a blinatumomab biosimilar rival to Amgen’s Blincyto.
Generics Bulletin - December 18, 2025
Regulatory Recap: UK-US Trade Deal Must Not Overlook Off-Patent Medicines
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - December 18, 2025
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - December 18, 2025
Polpharma-Libbs Licensing Deal Targets Brazil’s Biosimilar Autoimmune Market
Licensing agreement expands Polpharma’s footprint in Latin America while supporting Libbs’ strategy to grow access to advanced biologics in Brazil.
Generics Bulletin - December 18, 2025
Licensing agreement expands Polpharma’s footprint in Latin America while supporting Libbs’ strategy to grow access to advanced biologics in Brazil.
Generics Bulletin - December 18, 2025
Stada, Dr Reddy’s And Zentiva Sink Cabazitaxel Patent At UPC
Unified Patent Court ruling removes legal overhang on cabazitaxel generics already on the European market.
Generics Bulletin - December 18, 2025
Unified Patent Court ruling removes legal overhang on cabazitaxel generics already on the European market.
Generics Bulletin - December 18, 2025
Video Interview: Inside Asymchem’s Advanced R&D Capabilities in the UK
Watch this video to learn more about Asymchem’s expanding R&D capabilities at its European hub in Sandwich, England.
Scrip - December 18, 2025
Watch this video to learn more about Asymchem’s expanding R&D capabilities at its European hub in Sandwich, England.
Scrip - December 18, 2025
Deals Shaping The Industry, November 2025
An interactive look at pharma, medtech and diagnostics deals made during November 2025. Data courtesy of Biomedtracker.
In Vivo - December 18, 2025
An interactive look at pharma, medtech and diagnostics deals made during November 2025. Data courtesy of Biomedtracker.
In Vivo - December 18, 2025
Aphaia Pushes A Patient-First Vision For Obesity Care
The obesity field is entering the “sobering” phase of the hype cycle; GLP-1 drugs have opened the door but have limitations. Aphaia CSO Steffen-Sebastian Bolz talks to In Vivo about shifting the focus back to patient experience, not just maximal weight loss.
In Vivo - December 18, 2025
The obesity field is entering the “sobering” phase of the hype cycle; GLP-1 drugs have opened the door but have limitations. Aphaia CSO Steffen-Sebastian Bolz talks to In Vivo about shifting the focus back to patient experience, not just maximal weight loss.
In Vivo - December 18, 2025
Inductive Bio, Amgen Join ARPA-H’s Push To Replace Animal Tox With AI And Human Tissues
Inductive Bio receives $21m from ARPA-H to develop AI toxicity models using human tissues, partnering with Amgen to replace animal testing in drug development.
In Vivo - December 18, 2025
Inductive Bio receives $21m from ARPA-H to develop AI toxicity models using human tissues, partnering with Amgen to replace animal testing in drug development.
In Vivo - December 18, 2025
Health Systems Brace For CAR-T ‘Tsunami’
Industry warns healthcare infrastructure – not manufacturing – may be the real bottleneck as cell therapies eye mass-market diseases.
In Vivo - December 18, 2025
Industry warns healthcare infrastructure – not manufacturing – may be the real bottleneck as cell therapies eye mass-market diseases.
In Vivo - December 18, 2025
EC Fails To Address ‘Flawed Data’ On Cosmetics’ Contribution To Wastewater Pollution - Industry
An updated study on the extended producer responsibility costs associated with the Urban Wastewater Treatment Directive, released with the latest omnibus from the European Commission focusing on the environment, doesn't adjust the cosmetic industry’s expected financial contribution.
HBW Insight - December 18, 2025
An updated study on the extended producer responsibility costs associated with the Urban Wastewater Treatment Directive, released with the latest omnibus from the European Commission focusing on the environment, doesn't adjust the cosmetic industry’s expected financial contribution.
HBW Insight - December 18, 2025
Oncolys’s 20-Year Journey To First Approval Filing
Oncolys reaches hard-won milestone with an approval filing in Japan for its oncolytic virus therapy telomelysin through the sakigake pathway, with the Japanese venture eyeing its first commercial launch in 2026.
Scrip - December 18, 2025
Oncolys reaches hard-won milestone with an approval filing in Japan for its oncolytic virus therapy telomelysin through the sakigake pathway, with the Japanese venture eyeing its first commercial launch in 2026.
Scrip - December 18, 2025
Finance Watch: Athira Licenses Breast Cancer Drug, Raises Cash To Develop It
Public Company Edition: Athira licensed Phase III lasofoxifene from Sermonix and raised $90m plus up to $146m from warrants. Also, Immunovant, Immunome and Kodiak grossed $550m, $400m and $160m respectively, in follow-on offerings. Vor garnered $150m in a private placement.
Scrip - December 18, 2025
Public Company Edition: Athira licensed Phase III lasofoxifene from Sermonix and raised $90m plus up to $146m from warrants. Also, Immunovant, Immunome and Kodiak grossed $550m, $400m and $160m respectively, in follow-on offerings. Vor garnered $150m in a private placement.
Scrip - December 18, 2025
Lilly Eyes Quick FDA Approval For Orforglipron In Obesity, While Novo Submits CagriSema
Lilly, which has a Commissioner’s National Priority Voucher for the oral GLP-1, revealed orforglipron maintained weight loss in patients switching from Wegovy or Zepbound.
Scrip - December 18, 2025
Lilly, which has a Commissioner’s National Priority Voucher for the oral GLP-1, revealed orforglipron maintained weight loss in patients switching from Wegovy or Zepbound.
Scrip - December 18, 2025
Takeda’s Zasocitinib Marks Another Win In Late-Stage Pipeline Strategy
The drugmaker announced positive topline results from its two Phase III trials of zasocitinib, a TYK2 inhibitor, in plaque psoriasis.
Scrip - December 18, 2025
The drugmaker announced positive topline results from its two Phase III trials of zasocitinib, a TYK2 inhibitor, in plaque psoriasis.
Scrip - December 18, 2025
Padcev/Keytruda Combo Chalks Up Another Bladder Cancer Win
Positive topline data from the EV-304/KEYNOTE-B15 Phase III trial in cisplatin-eligible muscle invasive bladder cancer follows hot on the heels of the combination's stellar results in chemotherapy-ineligible patients.
Scrip - December 18, 2025
Positive topline data from the EV-304/KEYNOTE-B15 Phase III trial in cisplatin-eligible muscle invasive bladder cancer follows hot on the heels of the combination's stellar results in chemotherapy-ineligible patients.
Scrip - December 18, 2025
Biotech Leader Afeyan Warns That ‘Scientific Method Is Under Attack’ In The US
The Flagship Pioneering founder warned the assault on science would not stop at mRNA technology or vaccines and urged the biopharma sector to speak up.
Scrip - December 18, 2025
The Flagship Pioneering founder warned the assault on science would not stop at mRNA technology or vaccines and urged the biopharma sector to speak up.
Scrip - December 18, 2025
Insmed’s Brensocatib Hits The Buffers In Sinusitis
Insmed’s brensocatib has comprehensively failed in a mid-stage study in chronic rhinosinusitis, which would have been a second potential blockbuster indication for the DPP1 inhibitor.
Scrip - December 18, 2025
Insmed’s brensocatib has comprehensively failed in a mid-stage study in chronic rhinosinusitis, which would have been a second potential blockbuster indication for the DPP1 inhibitor.
Scrip - December 18, 2025
Video Interview: Inside Asymchem’s Advanced R&D Capabilities in the UK
Watch this video to learn more about Asymchem’s expanding R&D capabilities at its European hub in Sandwich, England.
Scrip - December 18, 2025
Watch this video to learn more about Asymchem’s expanding R&D capabilities at its European hub in Sandwich, England.
Scrip - December 18, 2025
Oncolys’s 20-Year Journey To First Approval Filing
Oncolys reaches hard-won milestone with an approval filing in Japan for its oncolytic virus therapy telomelysin through the sakigake pathway, with the Japanese venture eyeing its first commercial launch in 2026.
Scrip - December 18, 2025
Oncolys reaches hard-won milestone with an approval filing in Japan for its oncolytic virus therapy telomelysin through the sakigake pathway, with the Japanese venture eyeing its first commercial launch in 2026.
Scrip - December 18, 2025
Execs On The Move: December 8–12, 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - December 18, 2025
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - December 18, 2025
FDA Announces ‘Common-Sense’ Reform, Expands RWE Use In Medical Device Reviews
The US FDA has made incorporating real-world evidence into medical device decisions a lot easier. The agency now says it will accept RWE without requiring it to contain identifiable individual patient data, making more of it available. Many stakeholders welcomed the change.
Medtech Insight - December 18, 2025
The US FDA has made incorporating real-world evidence into medical device decisions a lot easier. The agency now says it will accept RWE without requiring it to contain identifiable individual patient data, making more of it available. Many stakeholders welcomed the change.
Medtech Insight - December 18, 2025
US Consumers’ Tight Budgets Prompted Value Shift In Beauty, Less M&A Activity In 2025
Middle- and low-income US consumers are more thoroughly scrutinizing discretionary purchases, boosting mass market beauty sales in 2025 and prompting beauty companies to reposition their portfolios through reformulation, price reductions and packaging changes, says Capstone Partners.
HBW Insight - December 18, 2025
Middle- and low-income US consumers are more thoroughly scrutinizing discretionary purchases, boosting mass market beauty sales in 2025 and prompting beauty companies to reposition their portfolios through reformulation, price reductions and packaging changes, says Capstone Partners.
HBW Insight - December 18, 2025
Opella Study Finds ‘Significant Variation’ In Probiotic Quality In India
Only Opella’s own Enterogermina brand was found by a company-funded study to be contamination-free, to contain the claimed content, and show resistance to all tested antibiotics.
HBW Insight - December 18, 2025
Only Opella’s own Enterogermina brand was found by a company-funded study to be contamination-free, to contain the claimed content, and show resistance to all tested antibiotics.
HBW Insight - December 18, 2025
Vision Healthcare Grows VMS Offering With Sweden’s BioSalma
Vision Healthcare adds an established supplements portfolio, alongside a robust omni-channel set-up across the Nordics, with the acquisition of BioSalma.
HBW Insight - December 18, 2025
Vision Healthcare adds an established supplements portfolio, alongside a robust omni-channel set-up across the Nordics, with the acquisition of BioSalma.
HBW Insight - December 18, 2025
EC Fails To Address ‘Flawed Data’ On Cosmetics’ Contribution To Wastewater Pollution - Industry
An updated study on the extended producer responsibility costs associated with the Urban Wastewater Treatment Directive, released with the latest omnibus from the European Commission focusing on the environment, doesn't adjust the cosmetic industry’s expected financial contribution.
HBW Insight - December 18, 2025
An updated study on the extended producer responsibility costs associated with the Urban Wastewater Treatment Directive, released with the latest omnibus from the European Commission focusing on the environment, doesn't adjust the cosmetic industry’s expected financial contribution.
HBW Insight - December 18, 2025
Chime Biologics Partners With Libang Pharmaceuticals On A Biosimilar To Amgen’s Blincyto
Glancing over at the changing development requirements for biosimilars in the US and Europe, the Chinese duo Chime Biologics and Beijing Libang Pharmaceutical are allying to develop a blinatumomab biosimilar rival to Amgen’s Blincyto.
Generics Bulletin - December 18, 2025
Glancing over at the changing development requirements for biosimilars in the US and Europe, the Chinese duo Chime Biologics and Beijing Libang Pharmaceutical are allying to develop a blinatumomab biosimilar rival to Amgen’s Blincyto.
Generics Bulletin - December 18, 2025
Regulatory Recap: UK-US Trade Deal Must Not Overlook Off-Patent Medicines
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - December 18, 2025
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - December 18, 2025
Polpharma-Libbs Licensing Deal Targets Brazil’s Biosimilar Autoimmune Market
Licensing agreement expands Polpharma’s footprint in Latin America while supporting Libbs’ strategy to grow access to advanced biologics in Brazil.
Generics Bulletin - December 18, 2025
Licensing agreement expands Polpharma’s footprint in Latin America while supporting Libbs’ strategy to grow access to advanced biologics in Brazil.
Generics Bulletin - December 18, 2025
Stada, Dr Reddy’s And Zentiva Sink Cabazitaxel Patent At UPC
Unified Patent Court ruling removes legal overhang on cabazitaxel generics already on the European market.
Generics Bulletin - December 18, 2025
Unified Patent Court ruling removes legal overhang on cabazitaxel generics already on the European market.
Generics Bulletin - December 18, 2025
Deals Shaping The Industry, November 2025
An interactive look at pharma, medtech and diagnostics deals made during November 2025. Data courtesy of Biomedtracker.
In Vivo - December 18, 2025
An interactive look at pharma, medtech and diagnostics deals made during November 2025. Data courtesy of Biomedtracker.
In Vivo - December 18, 2025
Aphaia Pushes A Patient-First Vision For Obesity Care
The obesity field is entering the “sobering” phase of the hype cycle; GLP-1 drugs have opened the door but have limitations. Aphaia CSO Steffen-Sebastian Bolz talks to In Vivo about shifting the focus back to patient experience, not just maximal weight loss.
In Vivo - December 18, 2025
The obesity field is entering the “sobering” phase of the hype cycle; GLP-1 drugs have opened the door but have limitations. Aphaia CSO Steffen-Sebastian Bolz talks to In Vivo about shifting the focus back to patient experience, not just maximal weight loss.
In Vivo - December 18, 2025
Inductive Bio, Amgen Join ARPA-H’s Push To Replace Animal Tox With AI And Human Tissues
Inductive Bio receives $21m from ARPA-H to develop AI toxicity models using human tissues, partnering with Amgen to replace animal testing in drug development.
In Vivo - December 18, 2025
Inductive Bio receives $21m from ARPA-H to develop AI toxicity models using human tissues, partnering with Amgen to replace animal testing in drug development.
In Vivo - December 18, 2025
Health Systems Brace For CAR-T ‘Tsunami’
Industry warns healthcare infrastructure – not manufacturing – may be the real bottleneck as cell therapies eye mass-market diseases.
In Vivo - December 18, 2025
Industry warns healthcare infrastructure – not manufacturing – may be the real bottleneck as cell therapies eye mass-market diseases.
In Vivo - December 18, 2025